Basilea Pharmaceutica AG | |
Stock Exchange | Other OTC |
EPS |
$2.97 |
Market Cap |
$406.5 M |
Shares Outstanding |
11.87 M |
Public Float |
- |
Basilea Pharmaceutica AG | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
11.87 M |
Public Float |
- |
Basilea Pharmaceutica AG | |
Stock Exchange | SIX Swiss Exchange |
EPS |
CHF2.89 |
Market Cap |
CHF400.59 M |
Shares Outstanding |
11.88 M |
Public Float |
10.74 M |
Address |
Grenzacherstrasse 487 Basel Basel-Stadt (Basle Town) 4058 Switzerland |
Employees | - |
Website | http://www.basilea.com |
Updated | 07/08/2019 |
Basilea Pharmaceutica AG is a biopharmaceutical company, with focus on bacterial infections, fungal infections and cancer. The company engages in the discovery, development, and commercialization of pharmaceutical products. Its products include Cresemba Isavuconazole, Zevtera/Mabelio Ceftobiprole, Toctino, and Microbiology Test. |